Clinical trials: Vessel Disease
Multiple Myeloma
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To assess the safety and tolerability (including local injection site tolerability) of…
- Trial name
- NCT04045795
- Testing
- isatuximab SAR650984 IV, pomalidomide, dexamethasone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 56 people
- Sponsor
- Sanofi
Multiple Myeloma
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
The purpose of this Phase II study is to evaluate the safety and effectiveness (good and bad effects) of carfilzomib given as a 30-minute infusion and at a dose of 70 mg/m2 to treat patients with multiple myeloma (MM), who are…
- Trial name
- NCT02294357
- Testing
- Carfilzomib, Dexamethasone, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Coronary Artery Disease
CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)
The purpose of this PMS registry, named e-CYPHER Stent Registry, is to collect post marketing surveillance data on the CYPHERTM Sirolimus-eluting Coronary Stent following marketing approval, when used in normal clinical practice…
- Trial name
- NCT00245401
- Testing
- CYPHERTM Sirolimus-Eluting Coronary Stent
- Volunteers
- 2,070 people
- Sponsor
- Cordis US Corp.
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Venous Thromboembolism
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)
- Trial name
- PREDICARE (NCT03099031)
- Testing
- Tinzaparin
- Where
- France
- Volunteers
- 420 people
- Sponsor
- LEO Pharma
Atherosclerosis of Native Arteries of the Extremities
ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
The primary objective of this trial is to evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA)…
- Trial name
- IMPERIAL (NCT02574481)
- Testing
- ELUVIA (Stent Implantation), Zilver PTX (Stent Implantation)
- Where
- 68 sites in United States, Austria and 5 more
- Volunteers
- 524 people
- Sponsor
- Boston Scientific Corporation
Hypertension and Cardiovascular Risk Factors
Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the…
- Trial name
- EXCEL (NCT00579254)
- Testing
- CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)
- Volunteers
- 112 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants…
- Trial name
- NCT06931405
- Testing
- BLU-808
- Where
- 47 sites in United States, Denmark and 4 more
- Volunteers
- 105 people
- Sponsor
- Blueprint Medicines Corporation
Multiple Myeloma
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
The purpose of this individual-patient investigational new drug (IND) single patient request (SPR) is to provide participants treatment with JNJ-68284528, an investigational product prior to its marketing authorization.
- Trial name
- NCT04452994
- Testing
- JNJ-68284528
- Sponsor
- Janssen Research & Development, LLC
Diabetic Foot Ulcer, Venous Leg Ulcer
Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center
Prospective, single-blinded, single-center, parallel group, randomized controlled trial (RCT) to assess rate and frequency of wound healing and associated financial savings, when using Medaxis debritom+ versus standard of care as…
- Conditions
- Diabetic Foot Ulcer, Venous Leg Ulcer, Surgical Wound Dehiscence, Traumatic Wounds
- Trial name
- EVIDENT (NCT04920253)
- Testing
- Study Device Debridement, SOC Debridement
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Medaxis, LLC
Lymphoma, Multiple Myeloma
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor
In the European Union (EU), plerixafor is indicated in combination with granulocyte colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells (HSCs) to the peripheral blood (PB) for collection and…
- Trial name
- NCT01362972
- Volunteers
- 7,801 people
- Sponsor
- Genzyme, a Sanofi Company
Coronary Artery Disease
NeoVas Bioresorbable Coronary Scaffold Registry Study
The NeoVas Bioresorbable Coronary Scaffold Registry Trial is a prospective, multi-center, single arm registry trial based on the NeoVas FIM study which verified the safety and effectiveness of NeoVas initially.
- Trial name
- NCT02305472
- Testing
- NeoVas BCS
- Where
- 27 sites in China
- Volunteers
- 825 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Hypertension
A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.
- Trial name
- NCT00389519
- Testing
- ramipril
- Where
- 100 sites in United States, Argentina and 7 more
- Volunteers
- 422 people
- Sponsor
- Pfizer
Coronary Atherosclerosis, Myocardial Infarction
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
The CANARY (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow) Study is a pivotal trial to evaluate criteria for defining a Lipid Core Plaque (LCP) that is at high risk of rupturing during standard of…
- Conditions
- Coronary Atherosclerosis, Myocardial Infarction, Coronary Plaque Embolization
- Trial name
- CANARY (NCT01268319)
- Testing
- Embolic Protection Device (EPD), Intracoronary Spectroscopy and Ultrasonic Evaluation, Angioplasty and Stent Implant
- Where
- 9 sites in United States
- Volunteers
- 85 people
- Sponsor
- Infraredx
Multiple Myeloma
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma
- Trial name
- NCT00532675
- Testing
- LBH589, Lenalidomide
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension
- Trial name
- NCT00654875
- Testing
- Aliskiren
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 328 people
- Sponsor
- Novartis
Ischemic Stroke
ThrombX Retriever for Acute Ischemic Stroke Trial
This trial is designed to assess the safety and effectiveness of the ThrombX Retriever.
- Trial name
- TRAC (NCT05270122)
- Testing
- Mechanical thrombectomy with ThrombX Retriever
- Volunteers
- 200 people
- Sponsor
- ThrombX Medical
Lower Extremity Chronic Venous Ulcers
Assessment of the Safety and Efficacy of DERMASTREAM™ - ENZYSTREAM™ System for the Treatment of Chronic Venous Ulcers
The study objectives are to evaluate DermastreamTM - EnzystreamTM system safety, tolerability and efficacy, as a potent method for debridement of nonhealing lower extremity chronic venous ulcers patients.
- Trial name
- ENZ-DER-002-IL (NCT00485329)
- Testing
- Papain
- Where
- 3 sites in Israel
- Volunteers
- 48 people
- Sponsor
- EnzySurge
Coronary Artery Disease
Phase 3 Safety and Imaging Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing Coronary Angiography
This study was designed to evaluate the ability of AI-700-enhanced rest-stress echocardiography to detect coronary artery disease (CAD) in patients with suspected ischemic heart disease who are indicated for coronary angiography.
- Trial name
- NCT00156845
- Testing
- AI-700 contrast-enhanced echocardiography
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Acusphere
Seizures, Urticaria and Angioedema
A Safety Study For Prevenar 13 Among Chinese Children
This is an observational study based on a population-based EHR database.
- Conditions
- Seizures, Urticaria and Angioedema, Apnea, Fever
- Trial name
- NCT03656939
- Where
- China
- Volunteers
- 21,240 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.